Asset Management One’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-19,325
Closed -$312K 996
2023
Q3
$312K Sell
19,325
-36,911
-66% -$1.06M ﹤0.01% 893
2023
Q2
$2.33M Buy
56,236
+42
+0.1% +$2.61K 0.01% 754
2023
Q1
$3.38M Buy
56,194
+2,357
+4% +$188K 0.02% 685
2022
Q4
$3.85M Sell
53,837
-3,545
-6% -$267K 0.02% 631
2022
Q3
$4.36M Buy
57,382
+4,646
+9% +$362K 0.02% 591
2022
Q2
$3.67M Sell
52,736
-200
-0.4% -$15.1K 0.02% 660
2022
Q1
$4.38M Sell
52,936
-419
-0.8% -$30.9K 0.02% 663
2021
Q4
$4.17M Sell
53,355
-1,421
-3% -$143K 0.01% 707
2021
Q3
$6.36M Buy
54,776
+1,598
+3% +$242K 0.02% 590
2021
Q2
$11.8M Buy
53,178
+1,039
+2% +$202K 0.04% 432
2021
Q1
$6.89M Sell
52,139
-1,154
-2% -$183K 0.03% 566
2020
Q4
$9.01M Buy
53,293
+40,410
+314% +$5.53M 0.04% 469
2020
Q3
$1.43M Hold
12,883
0.01% 805
2020
Q2
$764K Hold
12,883
﹤0.01% 854
2020
Q1
$868K Buy
12,883
+9,388
+269% +$742K 0.01% 825
2019
Q4
$295K Buy
+3,495
New +$282K ﹤0.01% 977

Other funds holding NVCR

Asset Management One's NVCR Position: Q4 2023 in Review

Asset Management One sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 19,325 shares — an estimated $312K sold.

Asset Management One first reported a position in NVCR in Q4 2019 and held it in 16 quarters. The position peaked at $11.8M in Q2 2021. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Asset Management One reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Asset Management One sold 19,325 NovoCure shares in Q4 2023, an estimated $312K.
  • Asset Management One first reported a position in NovoCure in Q4 2019 and held it in 16 quarters.
  • Asset Management One's NovoCure position peaked at $11.8M in Q2 2021.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Asset Management One's 13F filing for Q4 2023, filed 24 Jan 2024.